Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.
Lewitt MS
,
Hilding A
,
Ostenson CG
,
Efendic S
,
Brismar K
,
Hall K
.
???displayArticle.abstract???
AIMS/HYPOTHESIS: Insulin-like growth factor-binding protein-1 (IGFBP-1) production in the liver is inhibited by insulin, and low circulating levels are associated with the metabolic syndrome. The aim of this study was to evaluate the predictive role and change in IGFBP-1 concentrations during development of abnormal glucose regulation.
METHODS: IGFBP-1 levels were determined at baseline and at 10 years in an incident case-control prospective study of Swedish white men aged 35-56 years. Individuals with normal glucose tolerance at baseline who developed abnormal glucose tolerance during a 10 year period (n = 355) according to WHO criteria were pair-matched to controls for age and family history of diabetes.
RESULTS: Fasting IGFBP-1 concentrations were lower in individuals who later developed abnormal glucose regulation and correlated inversely with fasting proinsulin values (r = -0.48; p < 0.0001), and both were significant predictors. Individuals in the highest quartile at baseline for an algorithm incorporating fasting IGFBP-1, blood glucose, proinsulin and waist and height had a 40-fold increased risk of developing type 2 diabetes compared with the lowest quartile (95% CI 7.7-214). IGFBP-1 increased 32% (95% CI 17-49%) during the 10 years in those developing diabetes and was increased in relation to insulin levels, suggesting the emergence of hepatic insulin resistance. Moreover, elevated IGFBP-1 levels at follow-up were associated with higher 2 h glucose values during an OGTT.
CONCLUSIONS/INTERPRETATION: Low IGFBP-1 predicts the development of abnormal glucose regulation and, as an inhibitor of the insulin-like actions of insulin-like growth factors, elevated levels of IGFBP-1 after the development of diabetes may also play a pathophysiological role.
Bang,
Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand.
1991, Pubmed
Bang,
Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand.
1991,
Pubmed
Bar,
Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart.
1990,
Pubmed
Barrett-Connor,
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study.
1998,
Pubmed
Bjørnholt,
Prediction of Type 2 diabetes in healthy middle-aged men with special emphasis on glucose homeostasis. Results from 22.5 years' follow-up.
2001,
Pubmed
Båvenholm,
Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance.
2001,
Pubmed
Conover,
Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans.
1992,
Pubmed
DECODE Study Group, the European Diabetes Epidemiology Group.,
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.
2001,
Pubmed
Dinneen,
Effects of changing diagnostic criteria on the risk of developing diabetes.
1998,
Pubmed
Grill,
Hyperproinsulinemia and proinsulin-to-insulin ratios in Swedish middle-aged men: association with glycemia and insulin resistance but not with family history of diabetes.
2002,
Pubmed
Hadaegh,
Waist/height ratio as a better predictor of type 2 diabetes compared to body mass index in Tehranian adult men--a 3.6-year prospective study.
2006,
Pubmed
Harrela,
Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men.
2000,
Pubmed
Heald,
Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.
2002,
Pubmed
Heald,
Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations.
2001,
Pubmed
Heald,
C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups.
2003,
Pubmed
Herbert,
Coated charcoal immunoassay of insulin.
1965,
Pubmed
Hilding,
Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
1995,
Pubmed
Hilding,
Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus.
1993,
Pubmed
Hilding,
The impact of family history of diabetes and lifestyle factors on abnormal glucose regulation in middle-aged Swedish men and women.
2006,
Pubmed
Hilding,
Glucagon and GLP-1 stimulate IGFBP-1 secretion in Hep G2 cells without effect on IGFBP-1 mRNA.
2002,
Pubmed
Janssen,
Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease.
1998,
Pubmed
Juul,
Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.
2002,
Pubmed
Kalme,
Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men.
2005,
Pubmed
Kamoda,
The serum levels of proinsulin and their relationship with IGFBP-1 in obese children.
2006,
Pubmed
Kotronen,
Effect of liver fat on insulin clearance.
2007,
Pubmed
Kuhl,
Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity.
2005,
Pubmed
Lang,
Regulation of IGF binding protein-1 in hep G2 cells by cytokines and reactive oxygen species.
1999,
Pubmed
Laughlin,
The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study.
2004,
Pubmed
Lee,
Insulin-like growth factor-binding protein-1 response to insulin during suppression of endogenous insulin secretion.
1993,
Pubmed
Lewitt,
Altered response of insulin-like growth factor-binding protein 1 to nutritional deprivation in type 2 diabetes mellitus.
2005,
Pubmed
,
Echinobase
Lewitt,
Insulin-like growth factor-binding protein-1 modulates blood glucose levels.
1991,
Pubmed
Lewitt,
Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?
1991,
Pubmed
Liew,
Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men.
2005,
Pubmed
Lyssenko,
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes.
2005,
Pubmed
Mogul,
Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women.
1996,
Pubmed
Mohamed-Ali,
Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome.
1999,
Pubmed
Ohlson,
Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913.
1988,
Pubmed
Póvoa,
Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid.
1984,
Pubmed
Qiao,
Post-challenge hyperglycaemia is associated with premature death and macrovascular complications.
2003,
Pubmed
Qiu,
Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus.
2005,
Pubmed
Rajkumar,
Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice.
1995,
Pubmed
Rajpathak,
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults.
2008,
Pubmed
Samstein,
IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production.
1996,
Pubmed
Sandhu,
Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.
2002,
Pubmed
Shaw,
Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality.
1999,
Pubmed
Singleton,
Microvascular complications of impaired glucose tolerance.
2003,
Pubmed
Suikkari,
Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin.
1989,
Pubmed
Wang,
Specific cleavage of insulin-like growth factor-binding protein-1 by a novel protease activity.
2006,
Pubmed
Wareham,
Fasting proinsulin concentrations predict the development of type 2 diabetes.
1999,
Pubmed